Depo Provera Contraceptive Injection

Depo Provera Contraceptive Injection - Product Information

Depo Provera Contraceptive Injection is used for the prevention of pregnancy. It is also used for the treatment of gynecological disorders. Medroxyprogesterone is also used to treat endometriosis and works by lowering the quantity of certain hormones in the body and decreasing the growth of abnormal tissues that cause endometriosis.

Depo-Provera Injection is manufactured by Pfizer in Belgium as a 1 ml vial containing a sterile aqueous suspension of 150 mg of Medroxyprogesterone Acetate per ml. We also have in stock Generic Alesse (Ovral-L Contraceptive Tablets) which is also used to treat the same indications.

Name of the Drug

We supply original Depot Provera contraceptive injection manufactured by Pfizer in Belgium.

Manufacturer of Depo Provera Contraceptive Injection

 Pfizer (Manufactured in Belgium)
Website: www.pfizer.com

Active Ingredient present in Depo Provera Contraceptive Injection

The active ingredient present in Depot Provera contraceptive injection is Medroxyprogesterone Acetate. Each injection (1 ml vial ) contains 150 mg of Medroxyprogesterone Acetate.

Depo Provera Contraceptive Injection Dosage

The recommended dose of Depo-Provera for effective contraception is 150 mg every three months administered by deep Intramuscular injection in the gluteal or deltoid muscle.

Depo-Provera Contraceptive Injection Storage

Store Depo-Provera Contraceptive Injection upright at controlled room temperature 20°C to 25°C (68°F to 77°F). Protect from light.

Depo-Provera Injection - Contraindications

Depo Provera Contraceptive Injection is contraindicated in patients with a hypersensitivity to Medroxyprogesterone Acetate or any inactive ingredient present in Depo Provera injections. Depo Provera Injection is contraindicated in the following cases:

• Depo-Provera should not be used during pregnancy, either for diagnosis or therapy.
• Depo-Provera is contraindicated as a contraceptive at the above dosage in known or suspected hormone-dependent malignancy of breast or genital organs.
• Depo-Provera is contraindicated in patients with the presence or history of severe hepatic disease whose liver function tests have not returned to normal.
• Depo-Provera must not be administered to patients with abnormal uterine bleeding until a definite diagnosis has been established and the possibility of genital tract malignancy eliminated.

Warnings and Precautions When Using Depo-Provera Injection

Following are the warnings and precautions associated with Depo Provera therapy:
Loss of Bone Mineral Density:
Use of Depo-Provera contraceptive injection reduces serum oestrogen levels and is associated with significant loss of BMD due to the known effect of oestrogen deficiency on the bone remodelling system. Bone loss increases with increasing duration of use.

Menstrual Irregularity:
The administration of Depo-Provera CI usually causes disruption of the normal menstrual cycle. Bleeding patterns include amenorrhoea which is present in up to 30% of women during the first 3 months and increasing to 55% by month 12 and 68% by month 24. Besides there is irregular bleeding and spotting; Prolonged (duration greater than 10 days) episodes of bleeding are known to occur in up to 33% of women in the first 3 months of use decreasing to 12% by month 12. Rarely, heavy prolonged bleeding can occur.

Anaphylaxis:
Reports of anaphylactic responses (anaphylactic reactions, anaphylactic shock, anaphylactoid reactions) have been received.

Thrombo-embolic Disorders:
Should the patient experience pulmonary embolism, cerebrovascular disease or retinal thrombosis while receiving Depo-Provera, the drug should not be re-administered.

Ectopic Pregnancy:
Doctors have to be alert to the possibility of an ectopic pregnancy among women using Depo-Provera Contraceptive Injection who become pregnant or complain of severe abdominal pain.

Liver Function:
Discontinue Depo-Provera CI use if jaundice or acute or chronic disturbances of liver function develop.

Weight Gain:
Women tend to gain weight while on therapy with Depo-Provera CI.

Psychiatric Disorders:
Patients with a history of endogenous depression should be carefully monitored. Some patients may complain of premenstrual-type depression while on Depo-Provera therapy.

Abscess formation:
As with any intramuscular injection, especially if not administered correctly, there is a risk of abscess formation at the site of injection, which may require medical and/or surgical intervention.

History or emergence of the following conditions require careful consideration and appropriate investigation: migraine or unusually severe headaches, acute visual disturbances of any kind, pathological changes in liver function and hormone levels.

Patients with thromboembolic or coronary vascular disease should be carefully evaluated before using Depo-Provera CI.

A decrease in glucose tolerance has been seen in some patients treated with progestogens. The mechanism for this decrease is obscure. For this reason, diabetic patients should be carefully monitored while receiving progestogen therapy.

Fertility, Pregnancy And Lactation:
Doctors must check that patients are not pregnant before initial injection of Depo-Provera, and also if administration of any subsequent injection is delayed beyond 89 days (12 weeks and five days).

Effects on ability to drive and use machines:
Depo-Provera can cause headaches and dizziness. Patients must be advised not to drive or operate machinery if affected.

Depo Provera Injection Side Effects

The following Depo Provera injection side effects were commonly observed in more than 5% of patients being treated: menstrual irregularities (bleeding and/or amenorrhoea), weight changes, headache, nervousness, abdominal pain or discomfort, dizziness, asthenia (weakness or fatigue).

Side effects reported by 1% to 5% of patients using Depo-Provera were: decreased libido or anorgasmia, backache, leg cramps, depression, nausea, insomnia, leucorrhoea, acne, vaginitis, pelvic pain, breast pain, no hair growth or alopecia, bloating, rash, oedema, hot flushes.

Overdosage

Although an Depo-Provera Injection overdose is not usually considered dangerous, it may cause problems such as headaches, dizziness, Yellowing of the skin or the whites of the eyes (jaundice), Irregular menstruation, such as spotting or heavier or lighter periods, Breast pain, Bloating, Depression and Decreased libido (sex drive). Symptoms of Depo Provera overdose are more likely to occur with high doses, or when too much Depo-Provera is used over a long period of time.

Treatment for a Depo Provera Contraceptive injection overdose will normally involve supportive care, which consists of treating the symptoms that occur as a result of an overdose. Supportive care for a Depo-Provera overdose may include monitoring kidney and liver function. Other supportive treatment will depend on the individual symptoms that occur from the overdose, if any.

Depo-Provera Injection During Pregnancy

Stop using this medication and inform your doctor immediately if you become pregnant during treatment. Although Depo-Provera CI must not be administered during pregnancy, there appears to be little or no increased risk of birth defects in women who have inadvertently been exposed to Medroxyprogesterone Acetate injections during early pregnancy.

Nursing Considerations

Detectable amounts of the medicine have been observed in the milk of mothers receiving Depo-Provera Contraceptive injection .
Do not use this medication without telling your doctor if you are breast-feeding a baby.

Buy Depo-Provera Injection Online at Only $19 per Vial

You can buy Depo-Provera Injection online from Clear Sky Pharmacy at a cheap price. Depo-Provera 150 mg Contraceptive Injection, manufactured by Pfizer, Belgium is supplied in a box containing a 1 ml vial of 150 mg strength . The 150 mg injections cost only $19 per unit when you place an order for 15 vials.

Disclaimer

The above information is provided to the best of our knowledge and in good faith, it is without a warrant of any kind, expressed or implied.

Shipping Restriction